Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma - Fig 4

<p><b>Kaplan–Meier survival curves showing that low ASS1 expression (ASS1-low) is associated reduced overall survival (<i>p</i> = 0.005, A) and disease-free survival (<i>p</i> = 0.001, B) compared to those whose tumors are ASS1-high in the untreated cohort.</b> (C) and (D) Kaplan–Meier survival curves showing that ASS1-low is associated reduced overall survival (p = 0.04, C), but not disease-free survival (<i>p</i> = 0.13, D) compared to those whose tumors are ASS1-high in the treated cohort.</p

Multivariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.

<p>Multivariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.</p

Multivariate Cox Regression Analysis of Overall Survival in Treated Group.

<p>Multivariate Cox Regression Analysis of Overall Survival in Treated Group.</p

The average immunohistochemical scores of ASS1 expression is significantly lower in treated cohort than that in untreated cohort (<i>p</i> = 0.007).

<p>The average immunohistochemical scores of ASS1 expression is significantly lower in treated cohort than that in untreated cohort (<i>p</i> = 0.007).</p

Univariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.

<p>Univariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.</p

Univariate Cox Regression Analysis of Overall Survival in Treated Group.

<p>Univariate Cox Regression Analysis of Overall Survival in Treated Group.</p

Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer - Fig 4

<p>A. Immunoblotting for MAP4K5 and E-cadherin expression in HPDE cells, immortalized human pancreatic ductal cells, and pancreatic cancer cell lines. The 293T cells transfected with MAP4K5 cDNA construct saved as a positive control for immunoblotting. B. Pearson’s correlation analysis between the MAP4K5 mRNA and CDH1 mRNA expression by RNA-sequencing analysis in 11 pancreatic cancer cell lines.</p

Correlation of ASS1 Expression and Clinicopathologic Parameters in Untreated Group and Treated Groups.

<p>Correlation of ASS1 Expression and Clinicopathologic Parameters in Untreated Group and Treated Groups.</p

Expression of MAP4K5 in non-neoplastic pancreas and pancreatic ductal adenocarcinoma samples.

<p>Representative micrographs show the expression of MAP4K5 in normal pancreatic tissue (A) and chronic pancreatitis (B). The benign pancreatic ductal cells in normal pancreas and chronic pancreatitis show strong cytoplasmic staining for MAP4K5. The adjacent pancreatic acinar cells and pancreatic islet cells are either negative or have very low expression of MAP4K5. C & D, Representative micrographs show the loss of MAP4K5 expression in two different pancreatic ductal adenocarcinoma samples. Strong cytoplasmic staining for MAP4K5 in benign pancreatic ductal cells in the left upper corner in D served as internal positive control. Original magnifications: 200X.</p

Pearson’s correlation analysis between MAP4K5 and CDH1 mRNA expression measured by RNA sequencing analysis in 112 pancreatic ductal adenocarcinoma samples from The Cancer Genome Atlas (TCGA) data portal.

<p>Pearson’s correlation analysis between MAP4K5 and CDH1 mRNA expression measured by RNA sequencing analysis in 112 pancreatic ductal adenocarcinoma samples from The Cancer Genome Atlas (TCGA) data portal.</p